World Journal of Oncology Has Gained an Impact Factor of 5.2 by Journal Citation Reports
Bibliographic record
Abstract
World Journal of Oncology has been publishing original contributions describing basic research and clinical investigation that cover cellular, molecular, prevention, diagnosis, therapy, translational oncology, and prognosis aspects of cancer.All publications have been indexed in the National Library of Medicine's PubMed database since 2010, including 50 from 2022.Its robust collection of publications demonstrates its commitment to advancing the scientific understanding and clinical management of cancer.Journal Citation Reports (JCR), which is integrated with the Web of Science, is published annually by Clarivate, and provides journal impact factors (IFs) that rank academic journals in the natural and social sciences from all over the world.The 2022 version was published at the end of June 2023, and included 21,522 journals from 112 countries, where 13,668 were science journals and the rest included social science and arts and humanities journals.Data provided in the 2022 version prove to be an invaluable resource for researchers, librarians, and academic institutions as they make informed decisions about journal subscriptions and research dissemination.IF is calculated by dividing the number of citations for articles published in the Web of Science indexed journals in the previous 2 years during the index year by number of articles published in our journal in previous 2 years (Fig. 1).This year, World Journal of Oncology gained its first IF of 5.2.This means that the articles published during 2020 or 2021 in World Journal of Oncology have been cited 5.2 times on aver-age.This ranks World Journal of Oncology 47 of 317 journals in Oncology category of JCR.This is quite a triumph given that we are among the top prestigious journals, such as Cancer Science (IF = 5.7),American Journal of Cancer Research (IF = 5.3), International Journal of Oncology (IF = 5.2), Cancers (IF = 5.2), Molecular Cancer Research (IF = 5.2) and Chinese Journal of Cancer Research (IF = 5.1).In fact, World Journal of Oncology was ranked higher than some leading journals of the field such as Frontiers in Oncology, Breast Cancer, Cancer Medicine, JCO Oncology Practice, EJSO, BMC Cancer, Annals of Surgical Oncology, Breast Cancer Research and Treatment, and Oncology.As mentioned in our previous editorial article [1], World Journal of Oncology promotes articles from around the world to address diversity in oncology.To this end, we investigated the top 10 countries that contributed the most papers to the World Journal of Oncology in the most recent 3 years which were: USA, Japan, China, Mexico, Israel, India, Nepal, Nigeria, Canada, France, Germany, Greece, Indonesia, Italy, and Saudi Arabia (seven countries tied in nineth place), in that order.Among the most cited papers published in World Journal of Oncology during the last 2 years, one-third were on "global oncology".These include reports from developing countries including a review of personalized medicine in the developing world [2], reports on breast cancer in Jamaica [3], in Nigeria [4], and in Mexico [5], on oral cancer in the Gulf Cooperation Council Countries [6], on non-Hodgkin lymphoma [7], and on ovarian cancer [8] in Mexico.The remaining two-thirds were: four review articles on the epidemiology of renal cell carcinoma [9], management of melanoma [10], metastatic renal cell carcinoma [11], and rare urogenital cancers [12]; five original articles: the Surveillance Epidemiology and End Results (SEER) database analysis of esophageal cancer [13], sarcopenia and visceral adiposity on effect of immunotherapy [14] and as a biomarker [15] in non-small cell lung cancer, effect of rapamycin on the radio-sensitivity [16], and programmed death-ligand 1 receptor (PD-L1) expression as a prognosticator of triple negative breast cancer [17]; and four case reports: cervical cancer with OHVIRA (obstructed hemivagina and ipsilateral renal anomaly) syndrome [18], metformin on breast cancer with diabetes [19], scalp leiomyosarcoma management [20] and the lung cancer community [21] during coronavirus disease 2019 (COVID-19) pandemic.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.016 | 0.064 |
| Meta-epidemiology (narrow) | 0.004 | 0.001 |
| Meta-epidemiology (broad) | 0.004 | 0.002 |
| Bibliometrics | 0.020 | 0.009 |
| Science and technology studies | 0.003 | 0.003 |
| Scholarly communication | 0.018 | 0.006 |
| Open science | 0.003 | 0.003 |
| Research integrity | 0.009 | 0.012 |
| Insufficient payload (model declined to judge) | 0.039 | 0.030 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".